New lupus drug candidate enters early human testing
Disease control
Not yet recruiting
This early-stage study tests a new drug called budoprutug (TNT119) in 30 adults with active lupus who haven't responded well to standard treatments. The drug aims to reduce disease activity by targeting and depleting certain immune cells. The main goals are to check safety, find …
Phase: PHASE1, PHASE2 • Sponsor: Climb Bio, Inc. • Aim: Disease control
Last updated May 12, 2026 13:39 UTC